FDA Warning Letters
This article was originally published in The Silver Sheet
Hospira cited for QS reg violations; Dexcom failed to report MDRs to the agency in a timely fashion. Four warning letters listed by FDA from March 18 through April 17.
You may also be interested in...
SENZA PDN showed Nevro's HF10 spinal cord stimulation therapy provided sustained relief to patients with painful diabetic neuropathy. Results of a separate trial showed HF10 improved outcomes in patients with non-surgical refractory back pain.
No device-related warning letters were released by the US FDA the week of 19 January.
Following a €2.5m award from the European Commission’s EIC Accelerator Program, Paris based CorWave has become the first EU company to obtain EIC fund investment. The company is developing a new pulsatile LVAD.